AZN - AstraZeneca PLC ADR - Stock Price & Dividends

Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US0463531089

Cancer, Diabetes, Heart, Vaccines, Respiratory, Cardiovascular, RareDisease

AstraZeneca PLC is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines to improve people's lives. The company's portfolio of medicines includes treatments for various diseases and conditions, such as cancer, cardiovascular disease, diabetes, and respiratory disease.

Some of its notable products include Tagrisso, Imfinzi, and Lynparza for cancer treatment, as well as Farxiga and Brilinta for cardiovascular and metabolic disorders. The company also offers a range of medicines for respiratory diseases, including Symbicort, Pulmicort, and Daliresp. Additionally, AstraZeneca has a portfolio of vaccines, including Vaxzevria, Beyfortus, and FluMist, which help protect people from infectious diseases.

AstraZeneca's medicines are prescribed by primary care and specialty care physicians, and the company reaches its customers through a network of distributors and local representative offices in over 100 countries, including the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia.

The company is committed to innovation and collaboration, as evident in its agreement with Neurimmune AG to develop and commercialize NI006, a novel treatment for neurodegenerative diseases. With a rich history dating back to 1992, AstraZeneca has undergone significant transformations, including a name change from Zeneca Group PLC to AstraZeneca PLC in 1999. Today, the company is headquartered in Cambridge, United Kingdom, and is a leader in the global biopharmaceutical industry.

For more information about AstraZeneca's products, pipeline, and initiatives, please visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for AZN - AstraZeneca PLC ADR  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for AZN - AstraZeneca PLC ADR  - Stock Price & Dividends

AZN Stock Overview

Market Cap in USD 245,901m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1993-05-12

AZN Stock Ratings

Growth 5y 77.6
Fundamental 55.8
Dividend 38.16
Rel. Performance vs Sector 1.07
Analysts 4.38/5
Fair Price Momentum 81.07 USD
Fair Price DCF 49.98 USD

AZN Dividends

Dividend Yield 12m 1.83%
Yield on Cost 5y 4.09%
Dividends CAGR 5y 0.70%
Payout Consistency 96.7%

AZN Growth Ratios

Growth 12m 20.19%
Growth Correlation 12m 33%
Growth Correlation 3m 51%
CAGR 5y 17.38%
CAGR/Mean DD 5y 2.32
Sharpe Ratio 12m 0.75
Alpha vs SP500 12m 2.82
Beta vs SP500 5y weekly 0.57
ValueRay RSI 67.73
Volatility GJR Garch 1y 19.02%
Price / SMA 50 1.51%
Price / SMA 200 15.33%
Current Volume 3051.9k
Average Volume 20d 3058.7k

External Links for AZN Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of AZN stocks?
As of July 14, 2024, the stock is trading at USD 79.24 with a total of 3,051,911 shares traded.
Over the past week, the price has changed by +2.46%, over one month by -1.04%, over three months by +14.96% and over the past year by +20.78%.
What are the forecast for AZN stock price target?
According to ValueRays Forecast Model, AZN AstraZeneca PLC ADR will be worth about 88.8 in July 2025. The stock is currently trading at 79.24. This means that the stock has a potential upside of +12%.
Issuer Forecast Upside
Wallstreet Target Price 86.9 9.69
Analysts Target Price 83.7 5.64
ValueRay Target Price 88.8 12.0

AstraZeneca PLC ADR: Its Journey, Core, and Market Standing

History of AstraZeneca

AstraZeneca, a global name in the pharmaceutical and biopharmaceutical industry, was founded through the merger of Astra AB and Zeneca Group PLC in 1999. Astra AB of Sweden and Zeneca Group of the United Kingdom, both having rich histories in healthcare and chemicals, combined their strengths to form a powerhouse. This merger was not just a fusion of two companies but a strategic move to enhance research capabilities, expand product portfolios, and improve global presence in the competitive pharmaceutical market.

Core and Side Businesses

The core business of AstraZeneca revolves around the discovery, development, and commercialization of prescription medicines. The company operates primarily in three main therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory. AstraZeneca's efforts in these areas have led to the development of breakthrough therapies and treatments that have significantly impacted patients' lives worldwide.

Beyond its pharmaceutical ventures, AstraZeneca also invests in biotech startup companies through its venture fund arm. This not only helps the company stay at the forefront of biotechnological advancements but also diversifies its business interests and revenue streams.

Current Market Status

As of the latest update, AstraZeneca PLC ADR (NASDAQ:AZN) continues to be a prominent player in the pharmaceutical industry, with a robust presence in markets across the globe. The company's strategic collaborations, innovative drug pipeline, and a strong focus on research and development have positioned it well for sustainable growth. Investors and market analysts often highlight AstraZeneca's growth potential, especially in emerging markets and through its next-generation therapies.

The COVID-19 pandemic brought significant attention to AstraZeneca due to its development of a vaccine in collaboration with Oxford University. This not only showcased the company's rapid response capabilities in public health emergencies but also its commitment to addressing global health challenges.

In the ever-evolving world of healthcare and pharmaceuticals, AstraZeneca remains a key figure, pushing forward with its mission to deliver life-changing medicines and contribute to the betterment of global health.